Literature DB >> 11296484

Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas.

P Kunkel1, S Müller, P Schirmacher, D Stavrou, R Fillbrandt, M Westphal, K Lamszus.   

Abstract

Scatter factor/hepatocyte growth factor (SF/HGF) is a pleiotropic cytokine that has been implicated in glioma invasion and angiogenesis. The SF/HGF receptor, MET, has been found to be expressed in neoplastic astrocytes as well as in endothelial cells of the tumor vasculature. Both SF/HGF and MET expression have also been described to correlate with the malignancy grade of human gliomas. However, most glioblastoma cell lines lack SF/HGF expression, raising the question of the cellular origin of SF/HGF in vivo. Using in situ hybridization, we analyzed glioblastomas, anaplastic astrocytomas, diffuse astrocytomas, pilocytic astrocytomas, and normal brain for the expression of SF/HGF mRNA. We detected strong SF/HGF expression by the majority of the tumor cells and by vascular endothelial cells in all glioblastoma specimens analyzed. Combined use of in situ hybridization with fluorescence immunohistochemistry confirmed the astrocytic origin of the SF/HGF-expressiong cells. In contrast, CD68-immunoreactive microglia/macrophages, as well as vascular smooth muscle cells reactive to alpha-smooth muscle actin, lacked SF/HGF expression. In anaplastic, diffuse, and pilocytic astrocytomas, SF/HGF expression was confined to a subset of tumor cells, and signals were less intense than in glioblastomas. In addition, we detected SF/HGF mRNA in cortical neurons. SF/HGF expression was not up regulated around necroses or at tumor margins. MET immunoreactivity was observed in GFAP-expressing astrocytic tumor cells and endothelial cells as well as in a subset of microglia/macrophages. We conclude that in vivo, both autocrine and paracrine stimulation of tumor cells and endothelium through the SF/HGF-MET system are likely to contribute to tumor invasion and angiogenesis. Lack of SF/HGF expression by most cultured glioblastoma cells is not representative of the in vivo situation and most likely represents a culture artifact.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11296484      PMCID: PMC1920608          DOI: 10.1093/neuonc/3.2.82

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  27 in total

1.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

Review 2.  Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?

Authors:  Iris Helfrich; Dirk Schadendorf
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

3.  Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation.

Authors:  Qiuhong Yang; Ryan Moulder K; Mark S Cohen; Shuang Cai; Laird M Forrest
Journal:  BAOJ Pharm Sci       Date:  2015-01-05

4.  Multidimensional hydrogel models reveal endothelial network angiocrine signals increase glioblastoma cell number, invasion, and temozolomide resistance.

Authors:  Mai T Ngo; Elijah Karvelis; Brendan A C Harley
Journal:  Integr Biol (Camb)       Date:  2020-06-19       Impact factor: 2.192

Review 5.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.

Authors:  Roger Abounader; John Laterra
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

6.  Comparative genetic analysis of metachronous anaplastic oligoastrocytomas with extended recurrence-free interval.

Authors:  Ramon Martinez; Hans-Konrad Schackert; Matthias Kirsch; Werner Paulus; Stefan Joos; Gabriele Schackert
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

7.  An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Authors:  Fadila Guessous; Ying Zhang; Charles diPierro; Lukasz Marcinkiewicz; Jann Sarkaria; David Schiff; Sean Buchanan; Roger Abounader
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

8.  Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.

Authors:  Iris Helfrich; Inka Scheffrahn; Sönke Bartling; Joachim Weis; Verena von Felbert; Mark Middleton; Masahi Kato; Süleyman Ergün; Helmut G Augustin; Dirk Schadendorf
Journal:  J Exp Med       Date:  2010-03-01       Impact factor: 14.307

9.  Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value.

Authors:  Roberto Garcia-Navarrete; Esperanza Garcia; Oscar Arrieta; Julio Sotelo
Journal:  J Neurooncol       Date:  2009-10-25       Impact factor: 4.130

10.  Virtual glioblastoma: growth, migration and treatment in a three-dimensional mathematical model.

Authors:  S E Eikenberry; T Sankar; M C Preul; E J Kostelich; C J Thalhauser; Y Kuang
Journal:  Cell Prolif       Date:  2009-05-29       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.